Cargando…
Outcomes of metastatic neuroendocrine carcinoma of the gallbladder
BACKGROUND: Neuroendocrine carcinoma of the gallbladder (NECGB) is a rare pathological entity. They are found to be aggressive cancers. Treatment strategies are based largely on extrapolation from other small cell cancers. Survival is poor compared to adenocarcinoma. Data from low- and middle-income...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929769/ https://www.ncbi.nlm.nih.gov/pubmed/33680088 http://dx.doi.org/10.3332/ecancer.2021.1174 |
_version_ | 1783659981093994496 |
---|---|
author | Ghosh, Joydeep Chatterjee, Meheli Ganguly, Sandip Dabkara, Deepak Biswas, Bivas |
author_facet | Ghosh, Joydeep Chatterjee, Meheli Ganguly, Sandip Dabkara, Deepak Biswas, Bivas |
author_sort | Ghosh, Joydeep |
collection | PubMed |
description | BACKGROUND: Neuroendocrine carcinoma of the gallbladder (NECGB) is a rare pathological entity. They are found to be aggressive cancers. Treatment strategies are based largely on extrapolation from other small cell cancers. Survival is poor compared to adenocarcinoma. Data from low- and middle-income countries are sparse. METHODS: All patients with metastatic NECGB treated in our centre were identified. Their treatment details were captured from electronic medical records. Baseline characteristics were noted and survival was estimated using Kaplan–Meir method. RESULTS: A total of 15 patients were included. The median age was 55 years. Large cell comprises 2/15 and small cell was found in 13/15 patients. Chemotherapy was platinum-based in 12 patients. The response to first-line chemotherapy was partial in 3 (20%), stable disease in 2 (13.3%) and progressive disease in 10 (66.6%). After a median duration of follow-up of 12 months, the median progression free survival was 3 months and the median overall survival was 5 months. CONCLUSION: The outcomes of small cell gallbladder cancer are dismal, despite good response rate. More prospective data are required. |
format | Online Article Text |
id | pubmed-7929769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-79297692021-03-05 Outcomes of metastatic neuroendocrine carcinoma of the gallbladder Ghosh, Joydeep Chatterjee, Meheli Ganguly, Sandip Dabkara, Deepak Biswas, Bivas Ecancermedicalscience Clinical Study BACKGROUND: Neuroendocrine carcinoma of the gallbladder (NECGB) is a rare pathological entity. They are found to be aggressive cancers. Treatment strategies are based largely on extrapolation from other small cell cancers. Survival is poor compared to adenocarcinoma. Data from low- and middle-income countries are sparse. METHODS: All patients with metastatic NECGB treated in our centre were identified. Their treatment details were captured from electronic medical records. Baseline characteristics were noted and survival was estimated using Kaplan–Meir method. RESULTS: A total of 15 patients were included. The median age was 55 years. Large cell comprises 2/15 and small cell was found in 13/15 patients. Chemotherapy was platinum-based in 12 patients. The response to first-line chemotherapy was partial in 3 (20%), stable disease in 2 (13.3%) and progressive disease in 10 (66.6%). After a median duration of follow-up of 12 months, the median progression free survival was 3 months and the median overall survival was 5 months. CONCLUSION: The outcomes of small cell gallbladder cancer are dismal, despite good response rate. More prospective data are required. Cancer Intelligence 2021-01-14 /pmc/articles/PMC7929769/ /pubmed/33680088 http://dx.doi.org/10.3332/ecancer.2021.1174 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Ghosh, Joydeep Chatterjee, Meheli Ganguly, Sandip Dabkara, Deepak Biswas, Bivas Outcomes of metastatic neuroendocrine carcinoma of the gallbladder |
title | Outcomes of metastatic neuroendocrine carcinoma of the gallbladder |
title_full | Outcomes of metastatic neuroendocrine carcinoma of the gallbladder |
title_fullStr | Outcomes of metastatic neuroendocrine carcinoma of the gallbladder |
title_full_unstemmed | Outcomes of metastatic neuroendocrine carcinoma of the gallbladder |
title_short | Outcomes of metastatic neuroendocrine carcinoma of the gallbladder |
title_sort | outcomes of metastatic neuroendocrine carcinoma of the gallbladder |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929769/ https://www.ncbi.nlm.nih.gov/pubmed/33680088 http://dx.doi.org/10.3332/ecancer.2021.1174 |
work_keys_str_mv | AT ghoshjoydeep outcomesofmetastaticneuroendocrinecarcinomaofthegallbladder AT chatterjeemeheli outcomesofmetastaticneuroendocrinecarcinomaofthegallbladder AT gangulysandip outcomesofmetastaticneuroendocrinecarcinomaofthegallbladder AT dabkaradeepak outcomesofmetastaticneuroendocrinecarcinomaofthegallbladder AT biswasbivas outcomesofmetastaticneuroendocrinecarcinomaofthegallbladder |